The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Interius, one of the most advanced players, will cost $350m.
Posters and mini-orals include another VEGF bispecific.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Summit and Nuvalent have scored prized plenary spots.
Inclacumab fails, and osivelotor is on hold.
